よむ、つかう、まなぶ。
参考資料4 有効性評価に基づく子宮頸がん検診ガイドライン更新版2020年３月31日 (67 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_25869.html |
| 出典情報 | がん検診のあり方に関する検討会（第35回 5／25）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
83) ANCR: Association of Nordic Cancer Registries. CANCER SCREENING FACT
SHEET (2 PAGES)
SWEDEN – CERVIX – 2017. https://nordscreen.org/wp-content/
uplodes/2017/05/Cervix-Fact-Sheet-Sweden-2017.pdf (アクセス；2019 年 6 月 23 日)
84) Polman NJ, Snijders PJF, Kenter GG, Berkhof J, Meijer CJLM. HPV-based cervical
screening: Rationale, expectations and future perspectives of the new Dutch screening
programme. Prev Med. 2019; 119: 108-117.
85) Sharp L, Cotton SC, Cruickshank ME, Gray NM, Neal K, Rothnie K, Thornton AJ,
Walker LG, Little J; TOMBOLA Group. Long-term worries after colposcopy: which
women are at increased risk? Womens Health Issues. 2015; 25(5): 517-527.
86) de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous
S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero
O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida
M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suárez GA, Lombardi LE, Banjo A,
Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E,
Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva
E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos
T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI,
Nowakowski AM, Bornstein J, Muñoz N, Bosch FX; Retrospective International Survey
and HPV Time Trends Study Group. Human papillomavirus genotype attribution in
invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol.
2010; 11(11): 1048-1056.
87) Pirog EC, Lloveras B, Molijn A, Tous S, Guimerà N, Alejo M, Clavero O,
Klaustermeier J, Jenkins D, Quint WG, Xavier Bosch F, Alemany L, de Sanjosé S; RIS
HPV TT study group. HPV prevalence and genotypes in different histological subtypes
of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol. 2014; 27(12):
1559-1567.
88) Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WG, Richart RM,
Isacson C. Prevalence of human papillomavirus DNA in different histological subtypes
of cervical adenocarcinoma. Am J Pathol. 2000; 157(4): 1055-1062.
89) Park KJ, Kiyokawa T, Soslow RA, Lamb CA, Oliva E, Zivanovic O, Juretzka MM,
Pirog EC. Unusual endocervical adenocarcinomas: an immunohistochemical analysis
with molecular detection of human papillomavirus. Am J Surg Pathol. 2011; 35(5): 633646.
90) Wang SS, Sherman ME, Silverberg SG, Carreon JD, Lacey JV Jr, Zaino R, Kurman
RJ, Hildesheim A. Pathological characteristics of cervical adenocarcinoma in a multicenter US-based study. Gynecol Oncol. 2006; 103(2): 541-546.
SHEET (2 PAGES)
SWEDEN – CERVIX – 2017. https://nordscreen.org/wp-content/
uplodes/2017/05/Cervix-Fact-Sheet-Sweden-2017.pdf (アクセス；2019 年 6 月 23 日)
84) Polman NJ, Snijders PJF, Kenter GG, Berkhof J, Meijer CJLM. HPV-based cervical
screening: Rationale, expectations and future perspectives of the new Dutch screening
programme. Prev Med. 2019; 119: 108-117.
85) Sharp L, Cotton SC, Cruickshank ME, Gray NM, Neal K, Rothnie K, Thornton AJ,
Walker LG, Little J; TOMBOLA Group. Long-term worries after colposcopy: which
women are at increased risk? Womens Health Issues. 2015; 25(5): 517-527.
86) de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous
S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero
O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida
M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suárez GA, Lombardi LE, Banjo A,
Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E,
Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva
E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos
T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI,
Nowakowski AM, Bornstein J, Muñoz N, Bosch FX; Retrospective International Survey
and HPV Time Trends Study Group. Human papillomavirus genotype attribution in
invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol.
2010; 11(11): 1048-1056.
87) Pirog EC, Lloveras B, Molijn A, Tous S, Guimerà N, Alejo M, Clavero O,
Klaustermeier J, Jenkins D, Quint WG, Xavier Bosch F, Alemany L, de Sanjosé S; RIS
HPV TT study group. HPV prevalence and genotypes in different histological subtypes
of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol. 2014; 27(12):
1559-1567.
88) Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WG, Richart RM,
Isacson C. Prevalence of human papillomavirus DNA in different histological subtypes
of cervical adenocarcinoma. Am J Pathol. 2000; 157(4): 1055-1062.
89) Park KJ, Kiyokawa T, Soslow RA, Lamb CA, Oliva E, Zivanovic O, Juretzka MM,
Pirog EC. Unusual endocervical adenocarcinomas: an immunohistochemical analysis
with molecular detection of human papillomavirus. Am J Surg Pathol. 2011; 35(5): 633646.
90) Wang SS, Sherman ME, Silverberg SG, Carreon JD, Lacey JV Jr, Zaino R, Kurman
RJ, Hildesheim A. Pathological characteristics of cervical adenocarcinoma in a multicenter US-based study. Gynecol Oncol. 2006; 103(2): 541-546.